[go: up one dir, main page]

AR047384A1 - Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR047384A1
AR047384A1 ARP050100111A ARP050100111A AR047384A1 AR 047384 A1 AR047384 A1 AR 047384A1 AR P050100111 A ARP050100111 A AR P050100111A AR P050100111 A ARP050100111 A AR P050100111A AR 047384 A1 AR047384 A1 AR 047384A1
Authority
AR
Argentina
Prior art keywords
group
atom
cycloalkyl
alkyl
alkylene
Prior art date
Application number
ARP050100111A
Other languages
English (en)
Inventor
Ahmed Abouabdellah
Garcia Antonio Almario
Jacques Froissant
Christian Hoornaert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR047384A1 publication Critical patent/AR047384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Compuesto que responde a la formula (1): en la cual: m representa 0, 1, 2 o 3; n representa 0, 1, 2, o 3, X representa un átomo de O o de S o un grupo SO o SO2; %R1 y R2 representan, independientemente entre sí, un átomo de H o un grupo alquilo C1- 3, o R1 y R2 forman juntos un grupos -(CH2)p-, donde p representa un numero entero que va de 1 a 5 de forma tal que, n + p, sea un numero entero que vaya de 2 a 5 R3 representa un átomo de H o de F o un grupo hidroxi o metilo; R4 representa un grupo de formula general CHR5CONHR6 en la cual: R5 representa un átomo de H o un grupo alquilo C1-6 y R6 representa un átomo de H o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquileno C1-6; Y representa: un grupo Y1 elegido, especialmente, entre un fenilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo, triazinilo, tiazolilo, naftilo, quinolinilo, isoquinolinilo, ftalazinilo, quinazolinilo, quinoxalinilo, naftiridinilo, cinolinilo, benzofuranilo, dihidrobenzofuranilo, benzotienilo, dihidrobenzotienilo, indolilo, isoindolilo, indolinilo, benzimidazolilo, benzoxazolilo, benzisoxazolilo, benzotiazolilo, benzisotiazolilo, benzotriazolilo, benzoxadiazolilo, benzotiadiazolilo; el grupo Y1 está sustituido, eventualmente, por uno o varios sustituyentes Y2, idénticos o diferentes entre sí, o por un grupo Y3; Y2 representa un átomo de halogeno, un grupo ciano, nitro, alquilo C1-8, alcoxi C1-8, tioalquilo C1-8, fluoroalquilo C1-8, fluoroalcoxi C1-8, fluorotioalquilo C1-8, cicloalquilo C3-7, cicloalquiloxi C3-7, cicloalquilo C3-7-alquileno C1-8, cicloalquilo C3-7-alquiloxi C1-8, hidroxi, NR7R8, NHCOR7, NHSO2R7, COR7, CO2R7, CONR7R8, SO2R7, SO2NR7R8, -O-(alquileno C1-3)-O-, feniloxi, feniltio, fenilalquileno C1-8, fenilalquiloxi C1-8 o fenilalquiltio C1-8; Y3 representa un grupo elegido, especialmente, entre un fenilo, piridinilo, pirimidinilo, pirazinilo o piridazinilo; el o los grupos Y3 pueden ser sustituidos por uno o varios grupos Y2 idénticos o diferentes entre sí, R7 y R8 representan, independientemente entre sí, un átomo de H o un grupo alquilo C1-6, o forman con el átomo de N que los lleva un ciclo azetidina, pirrolidina, piperidina, morfolina, tiomorfolina, azepina, piperazina, eventualmente sustituido por un grupo alquilo C1-3 o bencilo; en estado de base, de sal de adicion con un ácido, de hidrato o de solvato.
ARP050100111A 2004-01-16 2005-01-13 Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica AR047384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0400389A FR2865205B1 (fr) 2004-01-16 2004-01-16 Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR047384A1 true AR047384A1 (es) 2006-01-18

Family

ID=34707893

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100111A AR047384A1 (es) 2004-01-16 2005-01-13 Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica

Country Status (28)

Country Link
US (3) US7439257B2 (es)
EP (1) EP1708994B1 (es)
JP (1) JP4705590B2 (es)
KR (1) KR101171462B1 (es)
CN (1) CN100537534C (es)
AR (1) AR047384A1 (es)
AT (1) ATE369336T1 (es)
AU (1) AU2005212868B2 (es)
BR (1) BRPI0506918A (es)
CA (1) CA2552565C (es)
CY (1) CY1106918T1 (es)
DE (1) DE602005001930T2 (es)
DK (1) DK1708994T3 (es)
ES (1) ES2289701T3 (es)
FR (1) FR2865205B1 (es)
HR (1) HRP20070421T3 (es)
IL (1) IL176769A (es)
MA (1) MA28343A1 (es)
ME (1) MEP26408A (es)
NO (1) NO20063681L (es)
NZ (1) NZ548530A (es)
PL (1) PL1708994T3 (es)
PT (1) PT1708994E (es)
RS (1) RS50518B (es)
RU (1) RU2392269C2 (es)
TW (1) TWI402067B (es)
WO (1) WO2005077898A1 (es)
ZA (1) ZA200605698B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) * 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
US7269708B2 (en) * 2004-04-20 2007-09-11 Rambus Inc. Memory controller for non-homogenous memory system
AU2006215080B2 (en) 2005-02-17 2011-03-10 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
US8197472B2 (en) 2005-03-25 2012-06-12 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US7918848B2 (en) 2005-03-25 2011-04-05 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
JPWO2008023720A1 (ja) * 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
ES2533463T3 (es) 2006-10-12 2015-04-10 Bhi Limited Partnership Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
JP5330260B2 (ja) * 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
TW200922581A (en) * 2007-08-15 2009-06-01 Glaxo Group Ltd Compounds
EP2205585A1 (en) * 2007-10-16 2010-07-14 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
US9968396B2 (en) 2008-05-27 2018-05-15 Maquet Cardiovascular Llc Surgical instrument and method
US9402680B2 (en) 2008-05-27 2016-08-02 Maquet Cardiovasular, Llc Surgical instrument and method
WO2009154976A2 (en) 2008-05-27 2009-12-23 Maquet Cardiovascular Llc Surgical instrument and method
TW201044234A (en) * 2009-06-08 2010-12-16 Chunghwa Picture Tubes Ltd Method of scanning touch panel
US9955858B2 (en) * 2009-08-21 2018-05-01 Maquet Cardiovascular Llc Surgical instrument and method for use
CN105837565A (zh) * 2010-01-20 2016-08-10 赛诺菲 烷基-杂环氨基甲酸酯衍生物，它们的制备和治疗应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605793A5 (fr) * 1974-03-05 1978-10-13 Soc Et Scient Et Ind Procédé de préparation de nouveaux N-(1benzylpyrrollidinil 2-alkyl) benzamides substitués
CA2308850C (en) * 1997-11-24 2007-07-10 The Scripps Research Institute Inhibitors of gap junction communication
SK15602000A3 (sk) * 1998-04-16 2001-03-12 Texas Biotechnology Corporation Zlúčeniny, ktoré inhibujú viazanie integrínov na ich receptory
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
JP2004532229A (ja) * 2001-04-27 2004-10-21 ブリストル−マイヤーズ　スクイブ　カンパニー 脂肪酸アミド加水分解酵素阻害剤
PL373970A1 (en) * 2002-02-08 2005-09-19 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
CA2501506C (en) * 2002-10-07 2014-02-11 Daniele Piomelli Modulation of anxiety through blockade of anandamide hydrolysis
ATE431342T1 (de) * 2002-10-08 2009-05-15 Scripps Research Inst Inhibitoren von fettsäureamidhydrolase
FR2850377B1 (fr) * 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
US7439257B2 (en) 2008-10-21
BRPI0506918A (pt) 2007-06-05
CA2552565A1 (fr) 2005-08-25
IL176769A (en) 2010-06-30
RU2006129640A (ru) 2008-02-27
TW200536524A (en) 2005-11-16
CN100537534C (zh) 2009-09-09
DE602005001930T2 (de) 2008-04-30
DK1708994T3 (da) 2007-11-26
RS50518B (sr) 2010-05-07
CA2552565C (fr) 2013-12-31
EP1708994B1 (fr) 2007-08-08
CN1922138A (zh) 2007-02-28
JP2007522111A (ja) 2007-08-09
WO2005077898A1 (fr) 2005-08-25
US20080312262A1 (en) 2008-12-18
PL1708994T3 (pl) 2008-01-31
HK1101283A1 (zh) 2007-10-12
US7674805B2 (en) 2010-03-09
AU2005212868B2 (en) 2011-04-21
KR20070000478A (ko) 2007-01-02
ES2289701T3 (es) 2008-02-01
RU2392269C2 (ru) 2010-06-20
ZA200605698B (en) 2007-11-28
DE602005001930D1 (de) 2007-09-20
FR2865205B1 (fr) 2006-02-24
PT1708994E (pt) 2007-10-02
FR2865205A1 (fr) 2005-07-22
IL176769A0 (en) 2006-10-31
AU2005212868A1 (en) 2005-08-25
MEP26408A (en) 2010-06-10
US8026258B2 (en) 2011-09-27
ATE369336T1 (de) 2007-08-15
EP1708994A1 (fr) 2006-10-11
TWI402067B (zh) 2013-07-21
US20070021424A1 (en) 2007-01-25
CY1106918T1 (el) 2012-09-26
MA28343A1 (fr) 2006-12-01
NZ548530A (en) 2010-02-26
HRP20070421T3 (hr) 2007-10-31
JP4705590B2 (ja) 2011-06-22
NO20063681L (no) 2006-09-18
US20100120845A1 (en) 2010-05-13
KR101171462B1 (ko) 2012-08-07

Similar Documents

Publication Publication Date Title
AR047384A1 (es) Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica
HRP20080024T3 (hr) Derivati alkilpiperazinskih i alkilhomopiperazinskih karboksilata, njihovo dobivanje i njihova upotreba kao inhibitori enzima faah
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
AR076562A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR056307A1 (es) Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas
AR076563A1 (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica
AR047848A1 (es) Analogos de rifamicina y composiciones farmaceuticas que los contienen.
AR049739A1 (es) Derivados de aril-piridina
CO5550472A2 (es) Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
DK1419773T3 (da) 4-Phenylpiperidinderivativer som modulatorer af dopaminneurotransmission
PE20030890A1 (es) Cumarinas utiles como biomarcadores
DE60018135D1 (de) Benzothiophenderivate, Benzofuranderivate und Indolderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
AR047818A1 (es) Derivados de piperidinilalquilcarbamatos, su preparacion y su aplicacion en terapeutica
AR040570A1 (es) Deriados de acilaminotiazol, su preparacion y su aplicacion en terapeutica
AR042746A1 (es) Derivados de arilalquilcarbamatos, su preparacion y su aplicacion en terapeutica.
AR050920A1 (es) Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
HRP20080077T3 (en) Substituted n-cyclohexylimidazolinones having an mch-modulatory effect
AR074119A1 (es) Derivados de carbamatos de alquil-heterociclos, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en el tratamiento de enfermedades neurologicas,infecciosas y gastrointestinales, entre otras.
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos
AR047383A1 (es) Derivados de acilaminotiazol, su preparacion y su aplicacion en terapeutica
CO4750652A1 (es) Derivados de azacicloalcanos, su preparacion y sus aplica- ciones en terapeutica
HN2005000239A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
AR068372A1 (es) Derivados de n-fenilacetamida, inhibidores de la enzima soat1, y composiciones farmaceuticas y cosmeticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration